Aytu BioPharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aytu BioPharma, Inc.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
US FDA Converges With Other Regulators On Insomnia Drug Warnings, But Broader Safety Disagreements Persist
US FDA will add boxed warnings to insomnia drugs, bringing it in line with other regulators, even as a study in JAMA Internal Medicine study indicates that national drug authorities often disagree more broadly over when to issue safety advisories.
Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.
Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Aytu Bioscience, Inc.
- Innovus Pharmaceuticals, Inc.
- Luoxis Diagnostics Inc
- Rosewind Corporation
- Vyrix Pharmaceuticals, Inc.
- Neos Therapeutics, Inc.
- Aytu BioScience, Inc.